Koers Arca Biopharma Inc Nasdaq
Aandelen
US00211Y2090
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 24,5 mln. 22,77 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -9 mln. -8,36 mln. | Nettowinst (verlies) 2023 | -5 mln. -4,65 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 42,06 mln. 39,09 mln. | Nettoliquiditeiten 2023 | 37,15 mln. 34,52 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-3,44
x | K/w-verhouding 2023 |
-4,59
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 98,71% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Keuer
CEO | Chief Executive Officer | 65 | 01-10-06 |
C. Dekker
DFI | Director of Finance/CFO | 60 | 10-05-21 |
Sharon Perry
LAW | General Counsel | - | 01-01-08 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Anders Hove
BRD | Director/Board Member | 58 | 16-02-17 |
Robert Conway
CHM | Chairman | 70 | 03-09-13 |
Linda Grais
BRD | Director/Board Member | 68 | 01-05-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |